

«INCIDENT_CUSTOMER»«AddressBlock»

Att.: «CONTACTNAME» / Laboratory Manager

3T

Dako reference number: CAPA00544

Recall Notification

Dear Valued Customer,

The purpose of this letter is to inform you that Dako has initiated a recall of specific lots of the EnVision™ FLEX/HRP visualization reagent, which is one of the components in Dako's EnVision™ FLEX/FLEX+ kits. We are writing to you as our records show that your laboratory has received the affected lot(s).

The following Product Code(s) and Lot Number(s) are affected by this recall:

Table 1 - List of affected product code(s) and lot number(s) used globally (except Japan)

Product Code	Product Description	Lot number of EnVision™ FLEX/FLEX+ Kit	Lot number(s) of EnVision™ FLEX/HRP vials (SM802)	
K8000	Envision™ FLEX, High pH (link)	20019097	20019374	-
		20020777	20019374	-
		20021381	20019374	20021979
K8002	Envision™ FLEX+, Mouse, High pH (link)	20019103	20019374	-
		20019113	20019374	20018981
		20020772	20019374	-
		20020773	20019374	-
		20023052	20019374	-
K8023	EnVision™ FLEX Mini Kit, High pH (Link)	20021362	20019374	-

Products code	Product Description	Lot number of EnVision™ FLEX/FLEX+ Kit	Lot number(s) of EnVision™ FLEX/HRP vials (DM822)	
K8010	EnVision™ FLEX, High pH (Dako Autostainer/Autostainer Plus)	20020792	20019012	20021978
		20021384	20019012	-

K8012	EnVision™ FLEX+, Mouse, High pH (Dako Autostainer/Autostainer Plus)	20020768	20019012	20020326
K8024	EnVision™ FLEX Mini Kit, High pH ((Dako Autostainer/Autostainer Plus)	20019099	20019012	20017712

Product Code	Product Description	Lot number of EnVision™ FLEX/FLEX+ Kit	Lot number(s) of EnVision™ FLEX/HRP vials (DM842)		
GV800	EnVision™ FLEX, High pH (Dako Omnis)	20019102	20019013	20017714	20018510

Table 2 - List of affected product code(s) and lot number(s) used in Japan

Product Code	Product Description	Lot number of EnVision™ FLEX/FLEX+ Kit	Lot number(s) of EnVision™ FLEX/HRP vials (SM802)
K8000	EnVision™ FLEX, High pH (Link), Japan	20020771	20019374

Product Code	Product Description	Lot number of EnVision™ FLEX/FLEX+ Kit	Lot number(s) of EnVision™ FLEX/HRP vials (DM822)
K8010	EnVision™ FLEX, High pH (Dako Autostainer/Autostainer Plus), Japan	20017918	20019012
		20019758	20019012
		20020785	20019012
		20021376	20019012
		20022298	20019012
K8024	EnVision™ FLEX Mini Kit, High pH (Dako Autostainer/Autostainer Plus), Japan	20019759	20019012
		20020779	20019012

*** the letters to the individual customers will only contain the lot numbers they have actually purchased**

Description of the problem

Dako has determined that there is a defect in one lot of a buffer used in the manufacturing of some corresponding lots of the EnVision™ FLEX/HRP visualization reagent. Specifically, some instances of moderate-to-strong non-specific staining and overly-strong specific staining have been observed when this visualization reagent was used with four antibodies against the biomarkers Epstein-Barr Virus (EBV), MUM-1, Wilms' Tumor1(WT1) Protein and Smooth Muscle Actin (SMA). Negative control antibodies in the same run were negative, and did not show the non-specific staining.

Complaints received from customers using the four antibodies referenced above alerted Dako to this issue. Dako has conducted an investigation of the issue and determined that the complaints were related to the specific lot numbers of the EnVision™ FLEX/FLEX+ kits specified in above table. The table also shows the affected EnVision™ FLEX/HRP visualization reagent lot numbers found in those kits.

Dako investigation findings

The non-specific staining that was observed included diffuse cytoplasmic and/or light to strong nuclear staining, depending on the tissues stained. Nuclear staining was most pronounced with the Epstein-Barr Virus antibody in human pharyngeal tonsil tissue. As part of Dako's investigation, additional representative antibodies were tested with the affected lots to cover the broad range of products which include polyclonal rabbit, monoclonal mouse and rabbit, nuclear stains, cytoplasmic stains and membrane stains. This testing included Ki-67, Estrogen Receptor and Progesterone Receptor and two negative isotype controls antibodies. The tested antibodies have titration curves sensitive to detection system changes, and cover tissue types that can show background staining in sub-optimal and/or the most challenging conditions. The antibodies performed appropriately in accordance with their specifications, and did not exhibit the non-specific staining identified in EBV, MUM-1, WT1 or SMA.

To date, Dako is not aware of any cases of patient misdiagnosis.

Affected Results

Based on our investigation, there is the possibility that non-specific staining could be mistaken for specific staining, leading to a false positive test result. In most cases, the non-specific staining is easily detectable by trained personnel, however we recommend that you reevaluate test results from the affected lots. Misdiagnosis is considered very unlikely to have occurred if:

- an appropriate negative control tissue was included in the test, **OR**
- the test specimen contained known negative elements or cell types, **AND**
- the primary antibody is used as an adjunct test, and not the sole basis for forming the diagnosis or treatment regime.

It is important that you determine the impact of this change in performance on patient results from the affected lots.



An Agilent Technologies Company

We advise you to take the following actions within 10 working days:

1. Check if you have any vials of the affected lots of EnVision™ FLEX/HRP in your laboratory, **highlighted in yellow** in the table above in this letter.
2. Destroy the affected vials.
3. Please confirm that you have received this information by returning the attached, fully completed Device Recall Form and return the Device Recall Form to **Dako QA Vigilance, by email dako.dkvigilance@dako.com**.

Please note: The completed form is required to request replacement product for any unused inventory that you have destroyed.

This information is required by the regulatory authorities and Dako is required to inform them of the progress of this recall. It is therefore essential that you complete this action even if you do not have any remaining product in your inventory.

Please contact your Dako representative if you have any questions regarding this recall, completing the Device Recall Form or would like assistance with any of our products.

Transmission of this notice:

We kindly ask you to inform those who need to be aware of this notification within your organization or any other organization, to where the affected or potentially affected product(s) have been transferred. Please ensure that your organization maintains awareness of this notice and the recommended steps until the corrective actions have been completed.

Thank you for your attention to this matter. We apologize for any inconvenience that this action may cause, and we appreciate your understanding as we take action to ensure patient and customer satisfaction.

Reporting to authorities:

The undersigned confirms that the appropriate Regulatory Agency has been notified.

Dako Representative:

Name: Barbara Drago

Function: Quality Assurance; Complaint and Vigilance Manager

Contact details: Barbara.Drago@Dako.com

Signature: 

Best Regards,

